StockData
Valion Bio, Inc. logo

Valion Bio, Inc. (VBIO) stock

VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.50−0.04 (-7.55%)

Close on Nov 18, 2026Market cap $2.09MP/E –Yield –

Valion Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Valion Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$14.67M. For fiscal 2025 it was -$7.04M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.04M–
FY2024Dec 31, 2024-$5.73M–
FY2023Dec 31, 2023-$8.63M–
FY2022Dec 31, 2022-$8.93M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.34M–
Q1 FY2026Mar 31, 2026-$5.02M–
Q4 FY2025Dec 31, 2025-$2.31M–
Q3 FY2025Sep 30, 2025-$2.01M–
Q2 FY2025Jun 30, 2025-$1.83M–
Q1 FY2025Mar 31, 2025-$889.00K–
Q4 FY2024Dec 31, 2024-$1.37M–
Q4 FY2023Dec 31, 2023-$1.77M–
Q3 FY2023Sep 30, 2023-$1.87M–
Q2 FY2023Jun 30, 2023-$2.46M–
Q1 FY2023Mar 31, 2023-$2.52M–
Q4 FY2022Dec 31, 2022-$2.23M–
Q3 FY2022Sep 30, 2022-$2.78M–
Q2 FY2022Jun 30, 2022-$1.75M–
Q1 FY2022Mar 31, 2022-$2.17M–

More Valion Bio figures

See a number that looks wrong?